Novo Nordisk at ObesityWeek 2026

Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website

Novo Nordisk brings 16 presentations to ObesityWeek 2026 in National Harbor, and exhibits at Booth 309, 715, Suite 7, Suite 7a, Suite 7b. Its program centers on semaglutide, including real-world results with the oral form and what patients and clinicians prefer in obesity medicines, plus the amylin-based drugs cagrilintide and CagriSema. One concrete item is how cagrilintide protects bone mass during weight loss.

OrganizationObesityWeek 2026 Attendance
Novo Nordisk
Bagsværd, Denmark
◆Platinum Sponsor
Large pharmaPlatinum Sponsor
Global healthcare company with a century of diabetes medicines, also treating obesity and rare blood and endocrine disorders, with its US arm in New Jersey.
Booth
Exhibiting at Booth 309, 715, Suite 7, Suite 7a, Suite 7b
Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm
Talk
Sat Nov 14
11:45am–1:15pm
The Missing Piece in the Obesity Puzzle: Exploring the Immunobiology of Obesity and the Role of Amylin
Explores obesity-related inflammation, how current drugs affect it, and evidence for emerging amylin-based therapies, including combined GLP-1 and amylin drugs.
Riverview Ballroom B
with University of Colorado Anschutz Medical Campus, University of Alabama at Birmingham, University of California, San Francisco +1 more
Metabolism and integrative physiologyClinical obesity care and professional practiceObesity pharmacotherapy and drug development
Talk
Sun Nov 15
9:45am–10:15am
Evidence Snapshot: Addressing Weight and CV Risk in Patients with Obesity
Reviews cardiovascular outcomes and chronic weight-management trial data in adults with overweight or obesity, with dosing and administration considerations.
with Washington Center for Weight Management & Research
Interventional and clinical studiesClinical obesity care and professional practiceObesity pharmacotherapy and drug developmentChronic disease and obesity complications
Poster
Sun Nov 15
2:30pm–3:30pm
Poster
Sun Nov 15
2:30pm–3:30pm
AWS Cloud–First Data Discovery for Pragmatic Clinical Trial Linkage
Interventional and clinical studiesObesity pharmacotherapy and drug development
Poster
Sun Nov 15
2:30pm–3:30pm
Poster
Sun Nov 15
2:30pm–3:30pm
Poster
Sun Nov 15
2:30pm–3:30pm
Talk
Sun Nov 15
6:30pm–9:00pm
Obesity in Focus: Today's Evidence. Tomorrow's Possibilities.
Speakers cover what has changed in obesity guidelines, evidence behind approved obesity drugs, and the biology of amylin and new amylin analog data.
with UT Southwestern Medical Center, UTHealth Houston, University of Zurich +2 more
Interventional and clinical studiesClinical obesity care and professional practiceNutrition, diet and foodObesity pharmacotherapy and drug development
Talk
Mon Nov 16
11:30am–1:15pm
The Evolution of Obesity Management: Incorporating a Maturing Science into Clinical Practice
Case-based discussion of treating obesity as a lifelong chronic disease, with personalized drug choice, combination therapy and continued treatment.
Talk hosted by Azurity Pharmaceuticals
Riverview Ballroom A
with FlyteHealth
Clinical obesity care and professional practiceObesity pharmacotherapy and drug development
Poster
Mon Nov 16
2:30pm–3:30pm
Poster
Mon Nov 16
2:30pm–3:30pm

Explore the full ObesityWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in National Harbor. Leave your work email and we’ll be in touch.

Privacy

Download the full ObesityWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Novo Nordisk

Tell us what you sell and we’ll find the people at Novo Nordisk most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction